StatOrigin open statistical archive
Live Industries Statistics Regions Rankings Reports Compare Sources

C21 · Pharmaceuticals · 3 regions

GLP-1, incretin multi-agonist and amylin trial starts

Global: 223 in 2025, +16.8% on 2024.

  • 223 Latest · Global · 2025
  • +16.8% vs 2024
  • Annual Release cadence
  • 21 Records · 3 regions · 2020–2026

Verified 27 Sep 2026 · 1 publisher · Next period 2026

CSV JSON PNG Cite and reuse

Across regions

3 regions on one axis, spaced by time. Below it, the latest value of every region, ranked. Forecasts are dashed with hollow markers; the underlying values are one click away under the chart.

Fig 1 · C21 · 3 regions Annual

GLP-1, incretin multi-agonist and amylin trial starts by region

3 regions, 2020 to 2025

3 regions · 18 observations · 2020 to 2025
GLP-1, incretin multi-agonist and amylin trial starts by regionGLP-1, incretin multi-agonist and amylin trial starts by region. 3 regions on one axis: Global, United States, China. 18 observations from 2020 to 2025, ranging from 16 to 223. Latest values: Global 223 (2025); United States 107 (2025); China 54 (2025). 0 50 100 150 200 250 2020 2021 2022 2023 2024 2025 Global United States China
GLP-1, incretin multi-agonist and amylin trial starts by regionGLP-1, incretin multi-agonist and amylin trial starts by region. 3 regions on one axis: Global, United States, China. 18 observations from 2020 to 2025, ranging from 16 to 223. Latest values: Global 223 (2025); United States 107 (2025); China 54 (2025). 0 100 200 300 2020 2021 2022 2023 2024 2025 Global United States China
GLP-1, incretin multi-agonist and amylin trial starts by regionGLP-1, incretin multi-agonist and amylin trial starts by region. 3 regions on one axis: Global, United States, China. 18 observations from 2020 to 2025, ranging from 16 to 223. Latest values: Global 223 (2025); United States 107 (2025); China 54 (2025). 0 100 200 300 2020 2021 2022 2023 2024 2025 Global United States China
View the underlying data
GLP-1, incretin multi-agonist and amylin trial starts by region
Region Period Type Value
Global 2025 Actual 223
Global 2024 Actual 191
Global 2023 Actual 142
Global 2022 Actual 104
Global 2021 Actual 101
Global 2020 Actual 66
United States 2025 Actual 107
United States 2024 Actual 98
United States 2023 Actual 70
United States 2022 Actual 42
United States 2021 Actual 51
United States 2020 Actual 20
China 2025 Actual 54
China 2024 Actual 36
China 2023 Actual 40
China 2022 Actual 21
China 2021 Actual 18
China 2020 Actual 16
Source: ClinicalTrials.gov · CC BY 4.0 · statorigin.org
Fig 2 · C21 · Latest by region

GLP-1, incretin multi-agonist and amylin trial starts by region

Latest value per region, 2025

3 entries
GLP-1, incretin multi-agonist and amylin trial starts by regionGLP-1, incretin multi-agonist and amylin trial starts by region. 3 categories, highest is Global at 223. China United States Global 54 107 223
GLP-1, incretin multi-agonist and amylin trial starts by regionGLP-1, incretin multi-agonist and amylin trial starts by region. 3 categories, highest is Global at 223. China United States Global 54 107 223
GLP-1, incretin multi-agonist and amylin trial starts by regionGLP-1, incretin multi-agonist and amylin trial starts by region. 3 categories, highest is Global at 223. China United States Global 54 107 223
View the underlying data
GLP-1, incretin multi-agonist and amylin trial starts by region
Category Source Type Value
Global ClinicalTrials.gov Actual 223
United States ClinicalTrials.gov Actual 107
China ClinicalTrials.gov Actual 54
Source: ClinicalTrials.gov · CC BY 4.0 · statorigin.org

Every record

21 records · 3 regions · 2020–2026. Each period links to its record: the value, the quote it was read from, and the document.

GLP-1, incretin multi-agonist and amylin trial starts: every record, grouped by region, newest first.
Period Value Source Type
Global 7 records
2025 223 ClinicalTrials.gov · 31 Dec 2025
2024 191 ClinicalTrials.gov · 31 Dec 2024
1 Jan 2023 to 27 Sep 2026 798 ClinicalTrials.gov · 27 Sep 2026
2023 142 ClinicalTrials.gov · 31 Dec 2023
2022 104 ClinicalTrials.gov · 31 Dec 2022
2021 101 ClinicalTrials.gov · 31 Dec 2021
2020 66 ClinicalTrials.gov · 31 Dec 2020
United States 7 records
2025 107 ClinicalTrials.gov · 31 Dec 2025
2024 98 ClinicalTrials.gov · 31 Dec 2024
1 Jan 2023 to 27 Sep 2026 378 ClinicalTrials.gov · 27 Sep 2026
2023 70 ClinicalTrials.gov · 31 Dec 2023
2022 42 ClinicalTrials.gov · 31 Dec 2022
2021 51 ClinicalTrials.gov · 31 Dec 2021
2020 20 ClinicalTrials.gov · 31 Dec 2020
China 7 records
2025 54 ClinicalTrials.gov · 31 Dec 2025
2024 36 ClinicalTrials.gov · 31 Dec 2024
1 Jan 2023 to 27 Sep 2026 178 ClinicalTrials.gov · 27 Sep 2026
2023 40 ClinicalTrials.gov · 31 Dec 2023
2022 21 ClinicalTrials.gov · 31 Dec 2022
2021 18 ClinicalTrials.gov · 31 Dec 2021
2020 16 ClinicalTrials.gov · 31 Dec 2020

Download this data

PNG chart SVG chart CSV data JSON series API

Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: ClinicalTrials.gov. Licence: CC BY 4.0.

Embed this chart

Free to embed anywhere, including commercially. The attribution bar is part of the chart.

<iframe src="https://statorigin.org/embed/pharmaceuticals--ctgov-glp1-trial-starts--regions" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="GLP-1, incretin multi-agonist and amylin trial starts by region" loading="lazy"></iframe>
<p><a href="https://statorigin.org/indicators/ctgov-glp1-trial-starts">GLP-1, incretin multi-agonist and amylin trial starts by region</a>, data from StatOrigin, CC BY 4.0</p>
Preview embed

Use and publication rights

  • View, cite and link: free

    Quote any number, cite this page or a single record, and link to it anywhere.

  • Copy, chart and republish: free with attribution

    The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (ClinicalTrials.gov); the chart files already carry that line.

  • The source documents: the publisher's terms

    Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.

How this measure is built

Definition
Count of interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
Measure
One slice of Clinical trial starts ( basis: clinicaltrials gov registry, counting rule: by start date, form: count, segment: glp1 ) . Total number of clinical trials initiated during a given period. Region and period are columns on every record, not slices.
Limitations
Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
Verification
Each value, unit, period and place was checked against its quote before publication. See the methodology and the corrections process.

Sources · 21 documents

Document Publisher Published Data points
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in any country ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States ClinicalTrials.gov — 1

Other slices of clinical trial starts

Frequently asked questions

What is the latest GLP-1, incretin multi-agonist and amylin trial starts?

Global: 223 in 2025, +16.8% on 2024.

Where does this data come from?

From 21 documents published by ClinicalTrials.gov. Every figure on this page links to its record, which quotes the sentence or table row the number was read from.

How often is it updated?

Annual. The newest published period is 2025; the next release should cover 2026. A new figure appears here once the publisher releases it and it passes verification.

Can I use this data?

Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.

Cite this page

Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.

StatOrigin. (2026). GLP-1, incretin multi-agonist and amylin trial starts [Data set]. Retrieved September 29, 2026, from https://statorigin.org/indicators/ctgov-glp1-trial-starts

"GLP-1, incretin multi-agonist and amylin trial starts." StatOrigin, 2026, https://statorigin.org/indicators/ctgov-glp1-trial-starts. Accessed 29 Sep. 2026.

StatOrigin. "GLP-1, incretin multi-agonist and amylin trial starts." Data set, 2026. Accessed September 29, 2026. https://statorigin.org/indicators/ctgov-glp1-trial-starts.

@misc{statorigin_ctgov_glp1_trial_starts_2026, title = {GLP-1, incretin multi-agonist and amylin trial starts}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/ctgov-glp1-trial-starts}, note = {Data set. Accessed 2026-09-29} }